<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323869</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-03730</org_study_id>
    <secondary_id>96655</secondary_id>
    <secondary_id>AVF3576s</secondary_id>
    <secondary_id>LUN0013</secondary_id>
    <nct_id>NCT00323869</nct_id>
  </id_info>
  <brief_title>Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial of Bevacizumab in Combination With Gemcitabine and Carboplatin in Patients With Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell Carcinoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as
      treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a open-label, phase 2, single-arm, multi-center study of bevacizumab combined with
      gemcitabine and carboplatin. This treatment is for newly-diagnosed advanced non-small cell
      lung cancer (NSCLC), excluding squamous cell carcinoma. All subjects will receive 15 mg/kg
      bevacizumab every 3 weeks cycle, 1000 mg/m² of gemcitabine on day 1 and 8 every 3 weeks cycle
      and carboplatin (AUC= 5 ) every 3 weeks. Carboplasm will be administered 1 hour prior to the
      gemcitabine infusion, bevacizumab will be administered 1 hour following chemotherapy
      infusion.

      Subjects will receive a maximum of 6 cycles of chemotherapy, but treatment with bevacizumab
      may continue as long as patients have no evidence of progressive disease and no significant
      treatment-related toxicities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>18 months</time_frame>
    <description>Median progression-free survival (PFS) was assessed as the time to disease progression; toxicity requiring treatment discontinuation; or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (CR + PR + SD)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions, by computed tomography (CT); bone scan; positron emission tomography (PET) scan; and/or magnetic resonance imaging (MRI) as necessary to assess diseasE
Response determined as the number of subjects with any clinical response (CR + PR + SD) per RECIST criteria.
Complete Response (CR) = disappearance of all target lesions
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, or appearance of new cancer lesions
Stable Disease (SD): No significant effect, does not meet criteria for PR or PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>To evaluate the safety of the combination regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response (PR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of subjects with PR per RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of subjects with CR per RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable Disease (SD)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of subjects with SD per RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-First Event</measure>
    <time_frame>18 months</time_frame>
    <description>Median time-to-first event, with events defined as disease progression, death, or toxicity requiring drug discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Number of subjects surviving 1 year after treatment initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Number of subjects surviving 2 years after treatment initiation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + carboplatin + gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab in combination with carboplatin and gemcitabine:
•Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles.
Carboplatin was administered before the gemcitabine infusion:
•Gemcitabine, administered 1000 mg/m² IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles
Bevacizumab was administered 1 hour after end of all chemotherapy infusions:
•Bevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody</description>
    <arm_group_label>Bevacizumab + carboplatin + gemcitabine</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>C225</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Nucleoside analog</description>
    <arm_group_label>Bevacizumab + carboplatin + gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Alkylating agent</description>
    <arm_group_label>Bevacizumab + carboplatin + gemcitabine</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>CBDCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Age 18 or higher

          -  Life expectancy of at least 3 months

          -  ECOG Performance status 0 to 1

          -  Advanced stage non-small cell lung cancer, NSCLC, Stage IIIB with malignant pleural
             effusion or Stage 4, excluding squamous cell histology, with measurable or evaluable
             disease

          -  No prior systemic therapy for advanced NSCLC (prior therapy for early stage disease
             with one regimen is acceptable if it was completed at least 6 months prior to study
             entry)

          -  Palliative radiotherapy to painful bony metastases is permitted prior to study entry
             if completed prior to initiation of study treatment, and there are no residual
             sequelae of therapy such as bone marrow suppression

          -  Willingness to use appropriate contraception to avoid pregnancy during the study

          -  Leukocytes ≥ 3,000/µL

          -  Absolute neutrophil count ≥ 1,500/ µL

          -  Platelets ≥ 100,000/ µL

          -  Total bilirubin within normal institutional limits

          -  AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limit of normal

          -  Creatinine: Within normal institutional limits

          -  Creatinine clearance ≥ 60 mL/min/1.73 m² for patients with creatinine levels above
             institutional normal

          -  Ability to sign informed consent

        Exclusion Criteria:

          -  Prior systemic treatment for advanced NSCLC (one prior regimen of up to 4 cycles of
             neoadjuvant or adjuvant therapy for early stage disease will be allowed, if completed
             at least 6 months prior to study entry)

          -  Known brain metastases

          -  Prior treatment with bevacizumab

          -  History of allergic reactions

          -  Sensitivity attributed to compounds of similar chemical or biologic composition to
             bevacizumab

          -  Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in any other experimental drug study

          -  Concomitant chemotherapy, radiotherapy, or investigational agents

          -  Evidence of bleeding diathesis

          -  Coagulopathy

          -  Use of anti-coagulant agents including warfarin, heparin, aspirin, NSAIDs

          -  Pregnant

          -  Lactating

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0, anticipation of need for major surgical procedure during the course of
             the study

          -  Minor surgical procedures within 7 days prior to day 0

          -  Fine needle aspirations within 7 days prior to day 0

          -  Core biopsies within 7 days prior to day 0

          -  Urine protein: creatinine ratio ≥ 1.0 at screening

          -  History of abdominal fistula within 6 months prior to Day 0

          -  Gastrointestinal perforation within 6 months prior to Day 0

          -  Intra-abdominal abscess within 6 months prior to Day 0

          -  Serious, non-healing wound

          -  Ulcer

          -  Bone fracture

          -  Lung carcinoma of squamous cell histology

          -  Any histology in close proximity to a major vessel

          -  Significant cavitation as assessed by treating investigator in consultation with an
             attending radiologist

          -  History of hemoptysis (bright red blood of 1/2 teaspoon or more)

          -  Blood pressure of &gt; 150/100 mmHg

          -  Unstable angina

          -  New York Heart Association (NYHA) Grade 2 or greater congestive heart failure

          -  History of myocardial infarction within 6 months

          -  History of stroke within 6 months

          -  Clinically significant peripheral vascular disease

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Another active malignancy except for non-melanoma skin cancers

          -  Inability to comply with study and/or follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather A Wakelee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Healthcare System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Medical Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Clément-Duchêne C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA. A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010 Nov;5(11):1821-5. doi: 10.1097/JTO.0b013e3181f1d23c.</citation>
    <PMID>20881641</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2006</study_first_submitted>
  <study_first_submitted_qc>May 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2006</study_first_posted>
  <results_first_submitted>April 20, 2016</results_first_submitted>
  <results_first_submitted_qc>June 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2016</results_first_posted>
  <last_update_submitted>July 30, 2016</last_update_submitted>
  <last_update_submitted_qc>July 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Heather Wakelee</investigator_full_name>
    <investigator_title>Associate Professor of Medicine (Oncology)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + Carboplatin + Gemcitabine</title>
          <description>Bevacizumab in combination with carboplatin and gemcitabine
Bevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity Gemcitabine, administered 1000 mg/m2 IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles
Carboplatin was administered before gemcitabine infusion.
Bevacizumab was administered 1 hour after end of all chemotherapy infusions.
Bevacizumab: Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
Gemcitabine: Nucleoside analog
Carboplatin: Alkylating agent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48">Enrollment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Initiation</title>
              <participants_list>
                <participants group_id="P1" count="47">One participant died before receiving therapy, not included in analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + Carboplatin + Gemcitabine</title>
          <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="35" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) performance status</title>
          <description>ECOG performance status
0 = Fully active, able to carry on all pre-disease performance without restriction
1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work, office work
2 = Unable to work, must sit or lie &gt; 50% waking hours
3 = Capable of limited selfcare; confined to bed or chair &gt; 50% waking hours
4 = Completely disabled; cannot carry on any selfcare; totally confined to bed/chair
5 = Deceased</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ECOG 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <description>Smoking status based on self-declaration between:
Never a smoker (&lt; 100 cigarettes in lifetime)
Quit and not currently a smoker
Currently a smoker.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never a smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Has stopped smoking (ex-smoker)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently a smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-small Cell Lung Cancer (NSCLC) Histology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchioloalveolar carcinoma (BAC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSCLC not otherwise specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-small Cell Lung Cancer Stage</title>
          <description>During the time of the trial patients with a malignant pleural effusion as only site of metastases were considered stage III-B (AJCC 6th edition). They were treated the same as stage IV (metastatic). Thus all patients included in this trial had advanced stage NSCLC and if staged under current staging criteria (AJCC 7th edition) all would be considered stage IV (metastatic).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NSCLC Stage III-B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSCLC Stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Median progression-free survival (PFS) was assessed as the time to disease progression; toxicity requiring treatment discontinuation; or death.</description>
        <time_frame>18 months</time_frame>
        <population>Includes all subjects who initiated treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Carboplatin + Gemcitabine</title>
            <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Median progression-free survival (PFS) was assessed as the time to disease progression; toxicity requiring treatment discontinuation; or death.</description>
          <population>Includes all subjects who initiated treatment</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="7.8" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (CR + PR + SD)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions, by computed tomography (CT); bone scan; positron emission tomography (PET) scan; and/or magnetic resonance imaging (MRI) as necessary to assess diseasE
Response determined as the number of subjects with any clinical response (CR + PR + SD) per RECIST criteria.
Complete Response (CR) = disappearance of all target lesions
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, or appearance of new cancer lesions
Stable Disease (SD): No significant effect, does not meet criteria for PR or PD.</description>
        <time_frame>6 weeks</time_frame>
        <population>Includes all subjects who initiated treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Carboplatin + Gemcitabine</title>
            <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (CR + PR + SD)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions, by computed tomography (CT); bone scan; positron emission tomography (PET) scan; and/or magnetic resonance imaging (MRI) as necessary to assess diseasE
Response determined as the number of subjects with any clinical response (CR + PR + SD) per RECIST criteria.
Complete Response (CR) = disappearance of all target lesions
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, or appearance of new cancer lesions
Stable Disease (SD): No significant effect, does not meet criteria for PR or PD.</description>
          <population>Includes all subjects who initiated treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>To evaluate the safety of the combination regimen.</description>
        <time_frame>36 months</time_frame>
        <population>Includes all subjects who initiated treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Carboplatin + Gemcitabine</title>
            <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>To evaluate the safety of the combination regimen.</description>
          <population>Includes all subjects who initiated treatment</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="10.0" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Response (PR)</title>
        <description>Number of subjects with PR per RECIST criteria</description>
        <time_frame>6 weeks</time_frame>
        <population>Includes all subjects who initiated treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Carboplatin + Gemcitabine</title>
            <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Response (PR)</title>
          <description>Number of subjects with PR per RECIST criteria</description>
          <population>Includes all subjects who initiated treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response (CR)</title>
        <description>Number of subjects with CR per RECIST criteria</description>
        <time_frame>6 weeks</time_frame>
        <population>Includes all subjects who initiated treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Carboplatin + Gemcitabine</title>
            <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (CR)</title>
          <description>Number of subjects with CR per RECIST criteria</description>
          <population>Includes all subjects who initiated treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stable Disease (SD)</title>
        <description>Number of subjects with SD per RECIST criteria</description>
        <time_frame>6 weeks</time_frame>
        <population>Includes all subjects who initiated treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Carboplatin + Gemcitabine</title>
            <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Stable Disease (SD)</title>
          <description>Number of subjects with SD per RECIST criteria</description>
          <population>Includes all subjects who initiated treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-First Event</title>
        <description>Median time-to-first event, with events defined as disease progression, death, or toxicity requiring drug discontinuation</description>
        <time_frame>18 months</time_frame>
        <population>Includes all subjects who initiated treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Carboplatin + Gemcitabine</title>
            <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-First Event</title>
          <description>Median time-to-first event, with events defined as disease progression, death, or toxicity requiring drug discontinuation</description>
          <population>Includes all subjects who initiated treatment</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="4.8" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) at 12 Months</title>
        <description>Number of subjects surviving 1 year after treatment initiation</description>
        <time_frame>12 months</time_frame>
        <population>Includes all subjects who initiated treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Carboplatin + Gemcitabine</title>
            <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) at 12 Months</title>
          <description>Number of subjects surviving 1 year after treatment initiation</description>
          <population>Includes all subjects who initiated treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) at 24 Months</title>
        <description>Number of subjects surviving 2 years after treatment initiation</description>
        <time_frame>24 months</time_frame>
        <population>Includes all subjects who initiated treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Carboplatin + Gemcitabine</title>
            <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) at 24 Months</title>
          <description>Number of subjects surviving 2 years after treatment initiation</description>
          <population>Includes all subjects who initiated treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <desc>All assessments were taken after every two cycles. Evaluations were taken the first 6 weeks, then every 3 weeks</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + Carboplatin + Gemcitabine</title>
          <description>Treatment provided in 3-week cycles:
15 mg/kg bevacizumab Day 1 of each cycle
1000 mg/m2 gemcitabine Days 1 and 8 of each cycle
Carboplatin (AUC of 5 every 3 weeks)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hemorrahage</sub_title>
                <description>Nose</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Platetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Liver Hemorrhage</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatreamia due to SIADH</sub_title>
                <description>SIADH- syndrome of inappropriate antidiuretic hormone</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <description>hyperbilirubinemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Possible Pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pulmonary Respiratory Distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutrophilis/Granolocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Chest</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather A Wakelee, MD, Associate Professor of Medicine (Oncology)</name_or_title>
      <organization>Stanford University Medical Center</organization>
      <phone>650-498-6000</phone>
      <email>hwakelee@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

